Plasma Desmosine and Abdominal Aortic Aneurysm Disease. Issue 20 (15th October 2019)

• Record Type: Journal Article
• Authors: Mordi, Ify R.; Forsythe, Rachael O.; Gellatly, Corry; Iskandar, Zaid; McBride, Olivia M.; Saratzis, Athanasios; Chalmers, Rod; Chin, Calvin; Bown, Matthew J.; Newby, David E.; Lang, Chim C.; Huang, Jeffrey T. J.; Choy, Anna‐Maria
• Is Part Of: Journal of the American Heart Association. Volume 8:Issue 20(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-10-15
• Subjects: abdominal aortic aneurysm -- aortic rupture -- desmosine -- elastin; Heart -- Diseases -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; Cerebrovascular disease -- Periodicals; Cardiology -- Periodicals; 616.1
• DOI: 10.1161/JAHA.119.013743
• Languages: English
• ISSNs: 2047-9980

Abstract

Abstract : Background: It is recognized that factors beyond aortic size are important in predicting outcome in abdominal aortic aneurysm (AAA) disease. AAA is characterized by the breakdown of elastin within the aortic tunica media, leading to aortic dilatation and rupture. The aim of this study was to investigate the association of plasma desmosine (pDES), an elastin‐specific degradation product, with disease severity and clinical outcome in patients with AAA. Methods and Results: We measured pDES and serum biomarker concentrations in 507 patients with AAAs (94% men; mean age, 72.4±6.1 years; mean AAA diameter, 48±8 mm) and 162 control subjects (100% men; mean age, 71.5±4.4 years) from 2 observational cohort studies. In the longitudinal cohort study (n=239), we explored the incremental prognostic value of pDES on AAA events. pDES was higher in patients with AAA compared with control subjects (mean±SD: 0.46±0.22 versus 0.33±0.16 ng/mL; P <0.001) and had the strongest correlation with AAA diameter ( r =0.39; P <0.0001) of any serum biomarker. After adjustment for baseline AAA diameter, pDES was associated with an AAA event (hazard ratio, 2.03 per SD increase [95% CI, 1.02–4.02]; P =0.044). In addition to AAA diameter, pDES provided incremental improvement in risk stratification (continuous net reclassification improvement, 34.4% [95% CI, −10.8% to 57.5%; P =0.09]; integrated discrimination improvement, 0.04 [95% CI, 0.00–0.15; P =0.050]). Conclusions: pDES concentrations predict disease severity and clinical outcomes in patients with AAA. Clinical Trial Registration: http://www.isrctn.com . Unique identifier: ISRCTN76413758.